Anika Therapeutics, Inc. (ANIK)
15.09
+0.47
(+3.21%)
USD |
NASDAQ |
Jun 26, 16:00
15.09
0.00 (0.00%)
After-Hours: 19:44
Anika Therapeutics Accounts Receivable (Quarterly) : 25.77M for March 31, 2026
Accounts Receivable (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Accounts Receivable (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 25.77M |
| December 31, 2025 | 23.69M |
| September 30, 2025 | 22.19M |
| June 30, 2025 | 23.96M |
| March 31, 2025 | 21.99M |
| December 31, 2024 | 23.59M |
| September 30, 2024 | 28.36M |
| June 30, 2024 | 33.77M |
| March 31, 2024 | 32.08M |
| December 31, 2023 | 26.36M |
| September 30, 2023 | 34.68M |
| June 30, 2023 | 36.74M |
| March 31, 2023 | 30.63M |
| December 31, 2022 | 34.63M |
| September 30, 2022 | 34.17M |
| June 30, 2022 | 32.17M |
| March 31, 2022 | 29.31M |
| December 31, 2021 | 29.84M |
| September 30, 2021 | 32.35M |
| June 30, 2021 | 29.43M |
| March 31, 2021 | 26.51M |
| December 31, 2020 | 24.10M |
| September 30, 2020 | 23.01M |
| June 30, 2020 | 24.09M |
| March 31, 2020 | 28.10M |
| Date | Value |
|---|---|
| December 31, 2019 | 23.08M |
| September 30, 2019 | 23.89M |
| June 30, 2019 | 23.07M |
| March 31, 2019 | 18.26M |
| December 31, 2018 | 20.78M |
| September 30, 2018 | 20.77M |
| June 30, 2018 | 23.39M |
| March 31, 2018 | 18.29M |
| December 31, 2017 | 23.82M |
| September 30, 2017 | 23.80M |
| June 30, 2017 | 30.45M |
| March 31, 2017 | 21.08M |
| December 31, 2016 | 27.60M |
| September 30, 2016 | 21.83M |
| June 30, 2016 | 24.60M |
| March 31, 2016 | 14.80M |
| December 31, 2015 | 21.65M |
| September 30, 2015 | 23.38M |
| June 30, 2015 | 19.17M |
| March 31, 2015 | 16.03M |
| December 31, 2014 | 17.15M |
| September 30, 2014 | 20.17M |
| June 30, 2014 | 19.24M |
| March 31, 2014 | 16.47M |
| December 31, 2013 | 18.74M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Accounts Receivable (Quarterly) Benchmarks
| MiMedx Group, Inc. | 46.03M |
| Perspective Therapeutics, Inc. | 0.058M |
| ABVC BioPharma, Inc. | -- |
| Enovis Corp. | 444.21M |
| Edwards Lifesciences Corp. | 775.70M |